药学研究
藥學研究
약학연구
JOURNAL OF PHARMACEUTICAL RESEARCH
2015年
4期
238-239
,共2页
浅表性膀胱癌%羟基喜树碱%热疗%复发
淺錶性膀胱癌%羥基喜樹堿%熱療%複髮
천표성방광암%간기희수감%열료%복발
Superficial bladder cancer%Hydroxycamptothecin( HCPT)%Hyperthermia%Recurrence
目的:研究羟基喜树碱( HCPT)膀胱灌注联合热疗对浅表性膀胱癌术后复发的影响。方法选择114例浅表性膀胱癌行经尿道膀胱肿瘤电切术患者为研究对象,采用随机数字表法分为观察组和对照组各57例,对照组单纯采用羟基喜树碱膀胱内灌注化疗,观察组采用羟基喜树碱膀胱内灌注联合体外热疗。比较两组复发情况及远期生存率。结果观察组6个月、1年、1.5年、2年复发率均明显低于对照组(3.51% vs 19.30%,10.53% vs 24.56%,14.04% vs 29.82%,14.04% vs 35.09%);2年生存率明显高于对照组(87.72% vs 73.68%)。结论羟基喜树碱膀胱灌注联合热疗能有效降低浅表性膀胱癌术后复发率,提高远期生存率。
目的:研究羥基喜樹堿( HCPT)膀胱灌註聯閤熱療對淺錶性膀胱癌術後複髮的影響。方法選擇114例淺錶性膀胱癌行經尿道膀胱腫瘤電切術患者為研究對象,採用隨機數字錶法分為觀察組和對照組各57例,對照組單純採用羥基喜樹堿膀胱內灌註化療,觀察組採用羥基喜樹堿膀胱內灌註聯閤體外熱療。比較兩組複髮情況及遠期生存率。結果觀察組6箇月、1年、1.5年、2年複髮率均明顯低于對照組(3.51% vs 19.30%,10.53% vs 24.56%,14.04% vs 29.82%,14.04% vs 35.09%);2年生存率明顯高于對照組(87.72% vs 73.68%)。結論羥基喜樹堿膀胱灌註聯閤熱療能有效降低淺錶性膀胱癌術後複髮率,提高遠期生存率。
목적:연구간기희수감( HCPT)방광관주연합열료대천표성방광암술후복발적영향。방법선택114례천표성방광암행경뇨도방광종류전절술환자위연구대상,채용수궤수자표법분위관찰조화대조조각57례,대조조단순채용간기희수감방광내관주화료,관찰조채용간기희수감방광내관주연합체외열료。비교량조복발정황급원기생존솔。결과관찰조6개월、1년、1.5년、2년복발솔균명현저우대조조(3.51% vs 19.30%,10.53% vs 24.56%,14.04% vs 29.82%,14.04% vs 35.09%);2년생존솔명현고우대조조(87.72% vs 73.68%)。결론간기희수감방광관주연합열료능유효강저천표성방광암술후복발솔,제고원기생존솔。
Objective To study the effect of HCPT bladder perfusion combined hyperthermia on preventing recurrence postoperative of superficial bladder cancer. Methods 114 cases superficial bladder cancer with transurethral bladder tumor resection were divided into observation group and control group,control group given HCPT bladder perfusion chemotherapy, observation group given HCPT bladder perfusion combined hyperthermia. Relapse and long-term survival rate were com-pared. Results Recurrence rates of observation group 6 months,1 year,1. 5 year,2 years were significantly lower than that control group(3. 51% vs 19. 30%,10. 53% vs 24. 56%,14. 04% vs 29. 82%,14. 04% vs 35. 09%);2 year survival rate were significantly higher than that control group(87. 72% vs 73. 68%). Conclusion HCPT bladder perfusion combined hyperthermia therapy can reduce superficial bladder cancer postoperative recurrence rate,improve long-term survival rate.